PMID- 34973080 OWN - NLM STAT- MEDLINE DCOM- 20230331 LR - 20230331 IS - 1432-1335 (Electronic) IS - 0171-5216 (Print) IS - 0171-5216 (Linking) VI - 148 IP - 11 DP - 2022 Nov TI - Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naive metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study. PG - 3029-3038 LID - 10.1007/s00432-021-03873-3 [doi] AB - PURPOSE: The aim of this retrospective review was to compare the efficacy and safety of the atezolizumab plus carboplatin and nab-paclitaxel regimen versus the carboplatin and nab-paclitaxel regimen as front-line management for treatment-naive, metastatic nonsquamous programmed death-ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) in a selected population. METHODS: Consecutive patients with untreated, metastatic nonsquamous PD-L1-positive NSCLC who initially received the atezolizumab plus carboplatin and nab-paclitaxel (ACN) regimen or carboplatin and nab-paclitaxel (CN) regimen were retrospectively identified in two medical institutions from 2017 to 2020. The co-primary end points were overall survival (OS) and progression-free survival (PFS); secondary end point was the rate of key adverse events (AEs). RESULTS: In sum, 171 patients were retrospectively analysed, 47 of whom were excluded according to the criteria used in this study, leaving 124 patients (ACN: n = 60, median age 64 years [range 46-75]; CN: n = 64, 63 years [47-72]). The median duration of follow-up was 27 months [range 1-37]. At the final follow-up, the median OS was 19.9 months (95% confidence interval [CI], 16.3-22.5) in the ACN group vs. 14.8 months (95% CI 12.5-17.2) in the CN group (hazard ratio [HR] 0.51, 95% CI 0.33-0.77; p = 0.001). A marked distinction in the median PFS was seen (8.5 months [95% CI 6.7-9.4] in the ACN group vs. in the CN group [5.1 months [95% CI 3.6-6.8; HR 0.60; 95% CI 0.38-0.95; p = 0.005]). The rates of the key AEs (neutropenia and anaemia) were greater in the ACN group than in the CN group (all p < 0.05), but these AEs were manageable. CONCLUSION: Among selected populations of individuals with treatment-naive, metastatic nonsquamous PD-L1-positive NSCLC, atezolizumab combined with carboplatin and nab-paclitaxel chemotherapy might have encouraging anticancer activity, with a tolerable safety profile. CI - (c) 2021. The Author(s). FAU - Xu, Bo AU - Xu B AD - Department of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, China. FAU - Cheng, Huihui AU - Cheng H AD - Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China. FAU - Li, Kunhong AU - Li K AD - Department of Anesthesiology, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 3, Gutian Road, Qiaokou District, Wuhan, 430000, China. AD - Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 3, Gutian Road, Qiaokou District, Wuhan, 430000, China. FAU - Lv, Yukai AU - Lv Y AD - Department of Pediatrics, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, China. FAU - Zeng, Xianshang AU - Zeng X AD - Department of Orthopaedics, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, China. FAU - Liu, Tao AU - Liu T AD - Department of Intensive Care Unit, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 3, Gutian Road, Qiaokou District, Wuhan, 430000, China. liutao050124@163.com. AD - Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 3, Gutian Road, Qiaokou District, Wuhan, 430000, China. liutao050124@163.com. FAU - Yu, Weiguang AU - Yu W AUID- ORCID: 0000-0001-9596-8572 AD - Department of Orthopaedics, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, China. FAU - Guo, Wenbo AU - Guo W AD - Department of Invasive Technology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, China. LA - eng PT - Journal Article DEP - 20220101 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (130-nm albumin-bound paclitaxel) RN - 0 (Albumins) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 52CMI0WC3Y (atezolizumab) RN - 0 (B7-H1 Antigen) RN - BG3F62OND5 (Carboplatin) RN - 0 (CD274 protein, human) RN - P88XT4IS4D (Paclitaxel) SB - IM MH - Aged MH - Humans MH - Middle Aged MH - Albumins/adverse effects MH - Antibodies, Monoclonal, Humanized MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - B7-H1 Antigen MH - Carboplatin/adverse effects MH - *Carcinoma, Non-Small-Cell Lung MH - *Lung Neoplasms/pathology MH - Paclitaxel MH - Retrospective Studies MH - Staining and Labeling PMC - PMC9508031 OTO - NOTNLM OT - Atezolizumab OT - Carboplatin OT - Chemotherapy OT - Non-small cell lung cancer OT - Programmed cell death-ligand 1 COIS- All the authors declare no conflict of interest associated with this manuscript. EDAT- 2022/01/02 06:00 MHDA- 2022/09/28 06:00 PMCR- 2022/01/01 CRDT- 2022/01/01 12:03 PHST- 2021/09/03 00:00 [received] PHST- 2021/11/25 00:00 [accepted] PHST- 2022/01/02 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2022/01/01 12:03 [entrez] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.1007/s00432-021-03873-3 [pii] AID - 3873 [pii] AID - 10.1007/s00432-021-03873-3 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2022 Nov;148(11):3029-3038. doi: 10.1007/s00432-021-03873-3. Epub 2022 Jan 1.